Last 439.80 INR
Change Today +4.75 / 1.09%
Volume 460.6K
BIOS On Other Exchanges
Symbol
Exchange
Natl India
As of 3:54 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

biocon ltd (BIOS) Snapshot

Open
437.70
Previous Close
435.05
Day High
444.00
Day Low
434.10
52 Week High
07/4/14 - 553.70
52 Week Low
01/7/15 - 402.30
Market Cap
88.0B
Average Volume 10 Days
564.1K
EPS TTM
20.74
Shares Outstanding
200.0M
EX-Date
07/10/14
P/E TM
21.2x
Dividend
5.00
Dividend Yield
1.13%
Current Stock Chart for BIOCON LTD (BIOS)

Related News

No related news articles were found.

biocon ltd (BIOS) Related Businessweek News

No Related Businessweek News Found

biocon ltd (BIOS) Details

Biocon Limited develops and sells biotechnology products for the pharmaceutical sector in India and internationally. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, opthalmics, peptides, oral anti-diabetic agents, anti-inflammatory agents, hepatoprotective agents, and probiotics; and biosimilars comprising human insulin, insulin glargine, insulin lispro, insulin aspart, erythropoietin, filgrastim, streptokinase, and monoclonal antibodies. The company also provides branded formulations in the areas of diabetology, oncotherapeutic, nephrology, cardiology, immunotherapy, comprehensive care and bioproducts; and out-licensing services. In addition, it offers contract manufacturing services, including mammalian cell culture fermentation, microbial cell culture fermentation, and synthetic chemistry to small-to-medium sized pharmaceutical and biotech companies; undertakes clinical research activities on discovering new biomarkers; and provides integrated contract research services to support discovery and development, for small and large molecules. The company was founded in 1978 and is headquartered in Bengaluru, India.

7,310 Employees
Last Reported Date: 06/26/14
Founded in 1978

biocon ltd (BIOS) Top Compensated Officers

Founder, Chairman, Managing Director, Member ...
Total Annual Compensation: 14.1M
Compensation as of Fiscal Year 2014.

biocon ltd (BIOS) Key Developments

Dr. Jeremy Levin Joins Biocon's Board of Directors

Biocon Ltd. announced that it has inducted Dr. Jeremy M. Levin as an additional independent director to its Board. Dr. Levin is among the 25 most influential people in the biopharmaceutical industry as recognized by FierceBiotech.

Vijay Kuchroo Joins Biocon Ltd' s Board of Directors as Additional Independent Director

Biocon Ltd, announced that it has inducted Dr. Vijay K. Kuchroo as an additional independent director to it's board. Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital and co-director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. He has just been appointed as the director of the newly formed Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital. Kuchroo's major research interests include autoimmune diseases, particularly the role of co-stimulation - the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, cell surface molecules and regulatory factors that regulate induction of T-cell tolerance and dysfunction. He also serves on the scientific advisory boards and works in advisory capacity to a number of big pharmaceutical companies. As an advisor to Biocon, Dr. Kuchroo has made significant contributions towards scientifically positioning Itolizumab developed by Biocon, as a potential novel therapeutic for autoimmune diseases.

Biocon Limited Announces Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and First Nine Months Ended December 31, 2014

Biocon Limited announced unaudited consolidated and standalone earnings results for the third quarter and first nine months ended December 31, 2014. For the quarter, on consolidated basis, the company announced net sales or income from operations, net of excise duty of INR 7,692.2 million compared to INR 7,072.8 million a year ago. Profit from operations before other income and finance costs were INR 1,036.5 million compared to INR 1,245.2 million a year ago. Profit from ordinary activities after finance costs before tax was INR 1,086.3 million compared to INR 1,365.5 million a year ago. Net profit was INR 974.8 million or INR 4.56 per diluted share compared to INR 1,103.9 million or INR 5.31 per diluted share a year ago. EBITDA was INR 1,700 million compared to INR 1,870 million for the same period a year ago. For the first nine months, on consolidated basis, the company announced net sales or income from operations, net of excise duty of INR 22,295.9 million compared to INR 21,301.3 million a year ago. Profit from operations before other income and finance costs were INR 3,496.8 million compared to INR 3,619.4 million a year ago. Profit from ordinary activities after finance costs before tax was INR 3,755.3 million compared to INR 3,996.0 million a year ago. Net profit was INR 3,116.7 million or INR 14.84 per diluted share compared to INR 3,118.4 million or INR 15.21 per diluted share a year ago. EBITDA was INR 5,480 million compared to INR 5,500 million for the same period a year ago. For the quarter, on standalone basis, the company announced net sales or income from operations, net of excise duty of INR 5,079.4 million compared to INR 5,034.4 million a year ago. Profit from operations before other income and finance costs were INR 491.2 million compared to INR 178.2 million a year ago. Profit from ordinary activities after finance costs before tax was INR 638.1 million compared to INR 783.6 million a year ago. Net profit was INR 572.8 million or INR 2.87 per diluted share compared to INR 599.6 million or INR 3.03 per diluted share a year ago. For the first nine months, on standalone basis, the company announced net sales or income from operations, net of excise duty of INR 15,813.2 million compared to INR 15,605.0 million a year ago. Profit from operations before other income and finance costs were INR 2,253.0 million compared to INR 2,532.8 million a year ago. Profit from ordinary activities after finance costs before tax was INR 3,659.5 million compared to INR 3,094.2 million a year ago. Net profit was INR 3,134.3 million or INR 15.72 per diluted share compared to INR 2,375.7 million or INR 12.02 per diluted share before giving impact of scheme of merger for earlier year and INR 12.30 per diluted share after giving impact of scheme of merger for earlier year a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOS:IN 439.80 INR +4.75

BIOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $15.07 USD -0.25
Cambrex Corp $33.95 USD -0.87
Depomed Inc $22.99 USD -0.07
Divi's Laboratories Ltd 1,756 INR -17.05
Piramal Enterprises Ltd 894.60 INR -4.20
View Industry Companies
 

Industry Analysis

BIOS

Industry Average

Valuation BIOS Industry Range
Price/Earnings 21.8x
Price/Sales 3.0x
Price/Book 2.7x
Price/Cash Flow 14.3x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCON LTD, please visit www.biocon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.